INZYInozyme Pharma, Inc.

Nasdaq inozyme.com


$ 5.54 $ 0.00 (0 %)    

Friday, 30-Aug-2024 15:59:55 EDT
QQQ $ 476.00 $ 5.61 (1.19 %)
DIA $ 416.44 $ 2.30 (0.56 %)
SPY $ 563.62 $ 5.33 (0.95 %)
TLT $ 96.60 $ -1.04 (-1.07 %)
GLD $ 231.30 $ -1.66 (-0.71 %)
$ 5.54
$ 5.54 x 158
$ 5.55 x 295
-- - --
$ 2.69 - $ 7.80
156,795
na
347.55M
$ 0.95
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-30-2024 10-Q
2 05-07-2024 03-31-2024 10-Q
3 03-12-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-22-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-15-2022 06-30-2022 10-Q
10 05-10-2022 03-31-2022 10-Q
11 03-15-2022 12-31-2021 10-K
12 11-09-2021 09-30-2021 10-Q
13 08-11-2021 06-30-2021 10-Q
14 05-12-2021 03-31-2021 10-Q
15 03-25-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
17 09-03-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jefferies-assumes-inozyme-pharma-at-buy-raises-price-target-to-17

Jefferies analyst Maury Raycroft assumes Inozyme Pharma (NASDAQ:INZY) with a Buy rating and raises Price Target to $17.

 hc-wainwright--co-reiterates-buy-on-inozyme-pharma-maintains-14-price-target

HC Wainwright & Co. analyst Edward White reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $14 price target.

 needham-reiterates-buy-on-inozyme-pharma-maintains-23-price-target

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.

 inozyme-pharma-q2-eps-044-misses-039-estimate

Inozyme Pharma (NASDAQ:INZY) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0....

 wedbush-reiterates-outperform-on-inozyme-pharma-maintains-15-price-target

Wedbush analyst David Nierengarten reiterates Inozyme Pharma (NASDAQ:INZY) with a Outperform and maintains $15 price target.

 hc-wainwright--co-reiterates-buy-on-inozyme-pharma-maintains-14-price-target

HC Wainwright & Co. analyst Edward White reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $14 price target.

 inozyme-pharma-announces-fda-fast-track-designation-for-inz-701-for-the-treatment-of-abcc6-deficiency

Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutica...

 wells-fargo-initiates-coverage-on-inozyme-pharma-with-overweight-rating-announces-price-target-of-14

Wells Fargo analyst Tiago Fauth initiates coverage on Inozyme Pharma (NASDAQ:INZY) with a Overweight rating and announces Pr...

 needham-reiterates-buy-on-inozyme-pharma-maintains-23-price-target

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.

 inozyme-pharma-q1-eps-038-misses-036-estimate

Inozyme Pharma (NASDAQ:INZY) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0....

 needham-reiterates-buy-on-inozyme-pharma-maintains-23-price-target

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.

 why-tilray-brands-shares-are-trading-lower-by-around-22-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter esti...

 b-of-a-securities-maintains-buy-on-inozyme-pharma-lowers-price-target-to-14

B of A Securities analyst Tazeen Ahmad maintains Inozyme Pharma (NASDAQ:INZY) with a Buy and lowers the price target from $1...

 needham-reiterates-buy-on-inozyme-pharma-maintains-23-price-target

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION